Medicover wins Invest Cyprus International Investment Awards 2022 (Jul, 2022)

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Following the investment in acquiring NIPD Genetics, Medicover has been recently awarded Invest Cyprus International Investment Awards, a prize honouring international investors, individuals and companies in recognition of their significant contribution to the Cyprus economy. The prestigious award has reached its 10th edition this year, and it has been targeting organisations that have invested directly in Cyprus and created added value for the local economy.

The award ceremony was held in Parklane Hotel in Limassol, under the auspices of the President of the Republic of Cyprus, Mr. Nicos Anastasiades and attended by political figures, industry leaders, investors and professionals from the services sector. Staffan Ternström has been presented the award and expressed his gratitude in front of the distinguished audience.

“This is a special recognition, and we are proud and honored to receive it. That is because our investment will be yielding for years to come, and I am not referring to a financial gain, but a meaningful impact to potentially millions of people around the world. We chose to invest in NIPD Genetics, a leading innovative biotechnology company whose advanced genetic testing services have tremendous potential. The investment strengthens Medicover’s position in the genetic market and provides a solid foundation for further development with advanced diagnostic products and solutions. We see this prestigious award as further motivation to carry out our mission: to improve and sustain health and wellbeing.”, said Staffan Ternström, COO Medicover, Diagnostic Services.

Medicover has signed a strategic partnership with NIPD Genetics in 2018 investing in the company’s research and development capabilities for new tests. The acquisition of NIPD Genetics was completed in January 2022, placing Medicover in a new growth chapter, and supporting the vision of becoming a market leader in genetic testing.

Last updated: June 8, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- accredited, GMP- and ISO9001, 15189 and 13485 certified

Are you a patient?

Are you a physician?